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Abstract 
I study the effects between significant R&D expenses and abnormal returns in the listed Nordic 
companies. The main objective of the study was to answer whether investors mis-value R&D 
investments represented by significant R&D increases. The initial hypothesis was that investors 
underreact to the R&D investments and abnormal positive return predictability exists. 
 
I used Eberhart et al (2004) to define significant R&D increases in companies listed in Finland, 
Denmark, Sweden, or Norway. Accounting and price data were acquired from Datastream & 
Thomson Reuters. I then constructed equal weighted, value weighted and long-short portfolios 
which I regressed using various factor regressions (Fama, French: 1995, 2015, Carhart: 1997). 
 
I found that significant abnormal returns were present in equal weighted companies and the 
abnormal returns were consistent across portfolios and regressions. Value weighted portfolios 
produced economically significant returns excluding the long-short portfolio. To control for 
industry and firm characteristics, I created pre-R&D increase and non- high technology subsample 
returns and I found that lower technology companies did not exhibit abnormal returns and that the 
firm performance before R&D increases was not significantly higher or lower. 
 
To control for alternative return explanations, I checked if the firms with R&D increases had 
significant market exposure during stock market turmoil. I found that firms did not have increased 
exposure to negative market conditions. In addition, I regressed two subsamples that were 
separated by an outlier in accounting figures. I found that the abnormal returns were not affected 
by this outlier. 
 
My results show that positive return predictability applies only to the smaller companies that 
operate in high technology industries. I interpret positive return predictability as investor 
underreaction to future benefits of R&D investments in these companies. This phenomenon is not 
applicable to large companies which show no predictability but show return characteristics with low 
book to market ratio companies which indicate that these firms contain intangible value and 
investors perceive positive prospects for them with respect to future performance. 
 
This study provides additional empirical evidence on the growing body of literature on R&D return 
predictability and how investors react to intangible information by providing an empirical test on 
the intangible information that is contained within significant increases in R&D expenditures. 
 
 
Keywords  Research and Development, Abnormal Returns, Intangible Information 
  
Aalto University, P.O. BOX 11000, 00076 AALTO 
www.aalto.fi 





Table of Contents 
 
1. Introduction .................................................................................................................................... 4 
2. Empirical Framework and Hypothesis ........................................................................................ 5 
2.1 Intangibility of R&D Benefits .................................................................................................... 5 
2.2 R&D Expenditures in Predicting Future Returns ....................................................................... 6 
2.3 Hypothesis .................................................................................................................................. 7 
3. Data ................................................................................................................................................. 8 
3.1 Nordic Accounting Standards .................................................................................................... 8 
3.2 R&D Increase Sample Selection Criterion ................................................................................. 8 
3.3 Sample & Descriptive Statistics ................................................................................................. 9 
4. Methodology ................................................................................................................................. 11 
4.1 Portfolio Approach ............................................................................................................... 11 
4.2 Measuring Abnormal Returns............................................................................................... 12 
5. Results ........................................................................................................................................... 13  
5.1 Regression Results for Equal Weighted and Value Weighted Portfolios  ........................... 13 
5.2 Regression Results for Subsamples ...................................................................................... 15 
6. Robustness Checks ....................................................................................................................... 17 
6.1 Risk Based Explanation for Return Predictability ................................................................ 17 
6.2 Accounting Standardization Subsamples  ............................................................................ 18 
7. Conclusions ................................................................................................................................... 20 
8. References ..................................................................................................................................... 21 








Research and Development (R&D) is a key part of value creation in modern companies. Without 
sufficient R&D activities or acquiring innovations, companies undermine their competitive abilities 
on the market. However, R&D investments are costly, and the benefits of the investments are 
uncertain, compared to other investment activities such as capacity expansions.  
The role of research and development in firm value has been studied extensively during the last 
decades, with many researchers addressing the question of market valuation of R&D investments. 
Empirical literature provides mixed evidence on the matter. Researchers have found that R&D is mis-
valued by the markets and that there exists positive return predictability with R&D investments 
(Chan, Martin, Kensinger: 1990, Chan, Lakonishok, Sougiannis: 2001, Eberhart, Maxwell, Siddique: 
2004, Cohen, Diether, Malloy: 2013). On the other hand, there is a growing body of literature that 
finds R&D investments associated with increased risk and thereby explaining the return predictability 
with risk premia (Berk, Green, Naik: 2004, Gu: 2015, Li: 2011, Zhang: 2015). 
In this study I will address the question if markets mis-value R&D investments in the Nordics, I find 
Nordic markets a particularly apt sample for this study due to the similar accounting methods which 
allows a better comparability over time (Agami, Monsen: 1995). I will follow Eberhart et al (2004) 
methodology by creating portfolios that contain companies that have large and unexpected increases 
in R&D expenditure and measuring abnormal returns through Fama French three-factor, five-factor 
and Carhart four-factor models (Fama, French: 1993, 2015, Carhart: 1997). Most of the literature 
focuses on US markets and therefore my study contributes international empirical evidence on the 
subject. 
The results indicate that there is some positive return predictability with R&D increases, since equal 
weighted portfolios produce significant abnormal returns consistently, while value weighted 
portfolios produce economically large but statistically insignificant returns consistent with Eberhart 
et al (2004) findings. After controlling for increased systematic risk through market betas during bear 
markets, I do not find that R&D intensive firms are exposed to increased systemic risk, but instead 
have reduced market beta during times of stock market downturn. However, these effects are not 
applicable to all stocks. It seems that smaller firms in high technology industries are subject to positive 
R&D return predictability. 
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This study contributes to the growing field of literature that investigates the link between stock returns 
and R&D by providing empirical evidence on the phenomenon in the Nordic markets. Additionally, 
this study contributes to the broad field of literature that investigates how markets react to intangible 
information by providing evidence through a test on how markets react to the intangible information 
that is contained within large increases in R&D expenditures.  
 
2. Empirical Framework and Hypothesis 
 
The key research question of this paper is whether investors mis-value R&D investments in the 
Nordics. In this section I will provide and summarize the key literature that I have considered when 
formulating my hypothesis and what factors should be considered when testing the hypothesis. To 
my knowledge most of the literature focuses heavily on the US markets with some international 
counterparts, while specific regions such as the Nordics have not yet received attention. 
 
2.1 Intangibility of R&D Benefits 
 
Although R&D is an investment decision, it is much harder for investors to evaluate its benefits 
compared to other investments. For example, it is much harder to measure the additional cash flows 
that are brought in by a new medicine than it is to measure the benefits of an increase in production 
capacity. These intangible benefits are contrasted by the tangible cost of R&D. Unlike regular 
investments, R&D is usually expensed instead of amortized, which provides a tangible cost for the 
investment.  
Daniel & Titman (2006) show that investors mis-value intangible information in companies which in 
turn results to negative return predictability, in addition their results are consistent with the behavioral 
explanation that investors are overconfident in their abilities to predict intangible information. 
However, it seems that investor overreaction which presents itself as a negative return relation is not 
observed when looking at increases in R&D expenses. Instead there seems to be investor 
underreaction towards R&D increases and that large R&D investments generate tangible benefits by 
providing significant increases in firm performance. (Chan, Lakonishok, Sougiannis: 2001, Eberhart, 




2.2 R&D Expenditures in Predicting Future Returns 
 
R&D as a return predictor has been widely discussed in the empirical literature. The general findings 
in the empirical literature support that increased R&D expenses predict future returns (Chan, Martin, 
Kensinger: 1990, Chan, Lakonishok, Sougiannis: 2001, Eberhart, Maxwell, Siddique: 2004, Li: 2011, 
Cohen, Diether, Malloy: 2013, Zhang: 2015, Gu: 2015). However, the specific mechanisms behind 
the return predictability are under debate. 
Some of the empirical literature attribute the return predictability as market mis-valuation of the 
intangible benefits provided by R&D (Chan, Lakonishok Sougiannis: 2001, Eberhart, Maxwell, 
Siddique: 2004, Cohen, Diether, Malloy: 2013). This mis-valuation is usually observed as a market 
underreaction, which in turn results in positive abnormal returns. However, there is mixed evidence 
if this underreaction applies to all companies. Chan et al (2001) found that technology firms with 
poor performance and high R&D intensity generate positive abnormal returns and this effect is not 
present in other firms. Eberhart et al (2004) in turn found evidence that R&D predicts positive 
abnormal returns in all stocks through a different definition of R&D intensive stocks and that R&D 
intensive firms are associated with abnormal growth in operating performance, providing evidence 
on how the intangible benefit of R&D investments are realized. 
Risk-based explanations argue that R&D investment is not in fact mis-valued by markets and that 
R&D intensive firms are riskier, because the outcomes of R&D projects are uncertain, and they 
require constant funding in order to be completed. This constant funding can be an issue for 
companies with financial constraints, and therefore a higher expected return is required due to the 
risk premium (Li: 2011, Zhang: 2015). However, alternative risk-based evidence exists that explains 
return predictability by increased systematic risk, because benefits  of R&D investments are realized 
in future cash flows that expose the firms to systematic risk (Berk, Green, Naik: 2004, Gu: 2015). 
To summarize, direct mechanisms behind R&D return predictability are still under debate, with many 
attributing it to investor mis-valuation, while alternative explanations suggest a risk-based mechanism 
(Chan, Martin, Kensinger: 1990, Chan, Lakonishok, Sougiannis: 2001, Eberhart, Maxwell, Siddique: 








My hypothesis relies on two arguments that rely on established phenomena in the scientific literature 
which are: investor mis-valuation of intangible information and positive R&D return predictability.  
Investors have difficulties in evaluating intangible information which is reflected in stock returns 
(Daniel, Titman: 2006). Since the benefits of R&D investments are tied to future cash flows and the 
project outcomes are uncertain, the benefits can be seen as intangible and hard to interpret (Eberhart, 
Maxwell, Siddique: 2004, Chan, Lakonishok, Sougiannis: 2001, Cohen, Diether, Malloy: 2013). 
However, the mis-valuation does not imply that the return predictability should be positive which I 
will elaborate on my second argument. 
Secondly, the significant R&D increases imply that firms are allocating a lot of capital into something 
that is considered risky which is understood by the investors. However, investors do not correctly 
value the benefits, or they allocate too much risk to the R&D investments which results in 
undervaluation of the R&D investments which is then corrected in the subsequent years followed by 
the investment. (Eberhart, Maxwell, Siddique: 2004, Chan, Lakonishok, Sougiannis: 2001, Cohen, 
Diether, Malloy: 2013). 
To summarize, I argue that investors are not able to value intangible information and when it comes 
to large R&D investments, they seem to take a pessimistic stance on the benefits of the R&D 
investments such as increases in operating performance. These arguments are based on earlier 
empirical evidence (Daniel, Titman: 2006, Eberhart, Maxwell, Siddique: 2004, Chan, Lakonishok, 
Sougiannis: 2001, Cohen, Diether, Malloy: 2013). From this I formulate my hypothesis which is 
shown below. 
 
H1: R&D increases generate positive long-term abnormal returns in the Nordic markets because 










I describe below justification for using Nordic accounting data and the process of sample selection. 
Price and accounting data were acquired from Datastream and Thomson Reuters and factor datasets 
were acquired from Kenneth R. French’s Data Library1 and AQR Fund Management’s2 open source 
datasets.  
3.1 Nordic Accounting Standards 
 
Since this thesis relies heavily on accounting data, it is prudent to review how different Nordic 
countries account standards are comparable. If the historical reporting standards between countries is 
vastly different, then the key figures used to construct sample data would essentially be incomparable 
between countries and this would in turn render the analysis section on a fragile foundation. 
I will justify the comparability of Nordic accounting data through the study that measures the 
harmonization of Nordic accounting standards (Agami, Monsen, 1995). In short, Nordic accounting 
standards have had a high level of harmonization since mid-20th century. This harmonization across 
countries also includes the reporting of R&D expenditures and the possibility to amortize them. It is 
important to note that the introduction of IAS/IFRS does change the accounting standards between 
countries and that this could result in inconsistencies in the data which I will address in section 6. 
 
3.2 R&D Increase Sample Selection Criterion 
 
To investigate my hypothesis, I need to describe R&D increases in a way that it resembles a firm 
event in addition to a firm characteristic that R&D is usually seen as. Therefore, instead of measuring 
R&D intensity figures such as R&D to assets, I need to measure the level of change in these R&D 
intensity figures. By measuring significant increases, I am able to pinpoint “events” where R&D is 
increased significantly. 
Criterion behind the significant R&D increases is arguably the most defining action in this study. 
Firstly, I need to define the metrics used that measure significant R&D increases. I will use Eberhart 
 
1 Kenneth R. French data library can be accessed through: 
https://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html 
2 AQR Fund Management provides their factor data in their insights section: https://www.aqr.com/Insights/Datasets 
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 et al (2004) methodology to define two key metrics that are used to measure firms R&D increases. 
These metrics are: R&D/Sales, R&D/Assets. Since R&D/Sales can be a rather noisy variable due to 
changes in revenue, it is prudent to also include R&D/Assets variable to measure changes in firm’s 
R&D intensity. In order to measure a significant R&D increase a firm must have at least 5% increase 
in R&D/Sales and R&D/Assets and R&D/Assets has to be at least 5% after the increase. Finally, 5% 
increase in R&D expenses is required.  
 
3.3 Sample & Descriptive Statistics 
 
I gathered my sample data from Thomson Reuters and Datastream. Full sample includes companies 
that have had R&D expenditures in their accounting data and that they have been listed in Finland, 
Denmark, Sweden, or Norway. The sample includes delisted companies to adjust for any survivorship 
bias. REIT stocks and financial stocks such as banks and investment firms are excluded from the 
sample. 
Table 1 
Below table shows summary statistics on sample firm characteristics listed in Finland, Denmark, Sweden, or 
Norway. Observation periods starts from 1974 and ends in 2019 and the observation number represents firm 
year observations. Description of the metrics are the following. RDA measures R&D expenditures relative to 
the firm’s total assets. RevGrwth is the annual revenue growth measured in percentages. Size is the total market 
capitalization measure in millions of euros. BM is the book to market ratio which is calculated by dividing the 
shareholder’s equity with the market capitalization of the firm. DE measures debt to equity ratio of the firm, 
the metric is calculated by dividing the total liabilities with the shareholder’s equity. Accounting data that was 
published before initial public offerings were excluded to ensure data quality. 
 
 Summary Statistics Full Sample  
Metric Min Max Median Mean 1st quarter 3rd quarter    
                 
RDA 0 6,95 0,004 0,046 0 0,038    
                 
RevGrwth -1 8134,3 0 0,7 -0,01 0,12    
                 
Size 0,02 232703,1 98,72 1065,62 26,57 477,08    
                 
BM 0 137,2 0,6 1,22 0,31 1,08    
                 
DE 0 390,1 1,08 1,55 0,56 1,73    
Number of observations = 11381            
 
There are few key takeaways notes that should be considered when looking at the figures. First the 
market capitalization varies extremely among the sample. This can be seen from the min and max 
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values for the size metric and from the differences between the mean and median figures. This 
indicates that the sample covers a wide range of companies ranging from micro-cap firms to large-
cap companies. Second is the low values in the RDA metrics which indicate that even though the 
sample is biased towards the R&D intensive firms, the overall R&D intensity of the sample is 
generally very low. However, I find it important to note that the Nordic sample is a lot smaller 
compared to the US samples and this results in biases in the sample of companies with significant 
R&D increases towards Chan et al (1990) classification of high technology industries that can be seen 
from appendix a. I showcase the characteristics of the companies with significant R&D increases in 
table 2. This sample is the key target group of my study and this shows the key characteristics of the 
sample companies after the significant R&D increases. 
Table 2 
Below table shows summary statistics on sample firm characteristics with significant R&D increases listed in 
Finland, Denmark, Sweden, or Norway. Observation periods starts from 1974 and ends in 2019 and the 
observation number represents firm year observations. Description of the metrics are the following. RDA 
measures R&D expenditures relative to the firm’s total assets. RevGrwth is the annual revenue growth. Size 
is the total market capitalization measure in millions of euros. BM is the book to market ratio which is 
calculated by dividing the shareholder’s equity with the market capitalization of the firm. DE measures debt 
to equity ratio of the firm, the metric is calculated by dividing the total liabilities with the shareholder’s equity. 
Accounting data that was published before initial public offerings were excluded to ensure data quality. 
 
 
Summary Statistics R&D Increase Sample 
Metric Min Max Median Mean 1st quarter 3rd quarter   
                
RDA 0 2,31 0,1 0,14 0,06 0,16   
                
RevGrwth -1 207,13 0,03 0,48 -0,04 0,17   
                
Size 0,77 232703,10 125,30 2074,85 39,38 433,6   
                
BM 0 14,19 0,39 0,63 0,21 0,70   
                
DE 0 159,40 0,73 1,32 0,35 1,28   
Number of observations = 1345          
 
From table 2 I can see that the distribution of the size metric is roughly the same as in the full sample 
meaning that the R&D increases are not limited to certain sized companies. Differences arise in the 
smaller book to market ratio which is consistent with earlier findings that firms with increased R&D 
intensity have lower book to market values (Chan, Lakonishok: 2001). Firms with high R&D 
increases seem to have high differences between the revenue growth figure which indicates that they 
do not differ significantly from the full sample.  
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It should also be noted that the maximum RDA value is missing from the R&D increase sample which 
indicates that even though the company has incredibly high R&D intensity, it has not increased 
suddenly to that high point. This indicates that the Eberhart et al (2004) methodology is able to capture 
a rather different sample compared to ranking companies by R&D measures. This in turn allows a 




4.1 Portfolio Approach 
 
Following Eberhart et al (2004), methodology of using a portfolio approach, I will create equal 
weighted and value weighted portfolios that comprise of the sample companies. Using this method, I 
can measure how market reacts to companies that have significant R&D increases on the long run. It 
is important to note that long-only portfolios have disadvantages of misallocating risk (Fama; 1998, 
Eberhart, Maxwell, Siddique: 2004) which in turn could translate to abnormal returns. In order to 
avoid this, I will create a long-short portfolio that is more capable of capturing firm specific risks and 
characteristics. 
As mentioned in the sections 3.2 and 3.3, the definition of companies that have significant R&D 
increases is a key decision in this thesis. Using this sample that I described earlier in section 3.3, I 
construct an equal weighted portfolio by including companies that have had a significant R&D 
increase in the past 60 months. To allow investors price in the information of the R&D increase, I 
will include a 3-month lag before including a stock in the portfolio (Eberhart, Maxwell, Siddique; 
2004). The portfolio is rebalanced monthly. 
As shown by the median and the 1st quintile of the sample in table 2, it is reasonable to assume that a 
large portion of the sample companies are small companies. Therefore, it is salient to create value 
weighted portfolios to control for the company size. The selection for the value weighted portfolio is 
identical its equal weighted counterpart. However, there are four different currencies in the Nordics: 
Swedish Krona, Norwegian Krona, Danish Krona and the Euro. In order to adjust the currency 
differences, I used end of month exchange rates from Reuters Eikon platform. The value weighted 
portfolio is rebalanced on a monthly basis. 
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Equal weighted and value weighted long-short portfolios are created by going long on the R&D 
increase portfolios and shorting portfolios which are comprised of companies that do not have 
significant R&D increases within the five-year period. The short stock portfolios are selected from 
the full sample meaning that the companies that are being shorted do also have R&D expenditures 
and the same industry exclusions apply to them. These short portfolios are rebalanced monthly in the 
same way as the long portfolios.  
 
4.2 Measuring Abnormal Returns 
 
I will regress the portfolio returns using Fama French three-factor, Fama French five-factor and 
Carhart four-factor models (Fama, French; 1993, 2015, Carhart: 1997). In order to capture more 
exposures to different characteristics, the five-factor model provides additional insight to firm 
attributes. It should be noted that both regressions will use European level factor data while the excess 
market returns are taken from AQR’s Betting Against Beta data library, momentum factor is also 
taken from the AQR’s Betting Against Beta data library. The excess market return and momentum 
factor are measured from Swedish markets since the portfolio companies are mostly from Sweden 
which is shown in appendix b. 
I have listed below three-factor and five-factor models. 𝑅𝑅𝑝𝑝𝑝𝑝 is the portfolio return that includes stocks 
at a month t if t is within the five year (60 month) period of the significant R&D increase. SMB is the 
return between portfolios of small stocks and large stocks. HML contains the return of portfolios that 
have high book to market ratio versus low book to market ratio. RMW is the return difference between 
stocks that have robust or weak profitability. CMA in turn represents return differences in stocks that 
invest conservatively versus aggressively while UMD is the return difference in stocks that have 
performed well and poorly in the past 12 months. (Fama, French; 2015, Carhart: 1997). Risk free rate 
𝑅𝑅𝑓𝑓𝑝𝑝 is the monthly return of US T-bill. For the long short portfolios, the risk-free rate is not needed 
since it is included in the portfolio return 𝑅𝑅𝑝𝑝𝑝𝑝. 
Three-Factor Model 
𝑅𝑅𝑝𝑝𝑝𝑝 − 𝑅𝑅𝑓𝑓𝑝𝑝 = 𝛼𝛼 +  𝑏𝑏𝑝𝑝�𝑅𝑅𝑀𝑀𝑀𝑀𝑀𝑀𝑝𝑝 − 𝑅𝑅𝑓𝑓𝑝𝑝� +  𝑠𝑠𝑝𝑝𝑆𝑆𝑆𝑆𝑆𝑆𝑝𝑝 +  ℎ𝑝𝑝𝐻𝐻𝑆𝑆𝐻𝐻𝑝𝑝 + 𝜀𝜀𝑝𝑝 
Four-Factor Model 









5.1 Regression results for Equal Weighted and Value Weighted Portfolios 
 
The three-factor and five-factor regression results for equal weighted and value weighted portfolios 
are found in table 3. The four-factor regression results are found in table 4. Three-factor and four-
factor regression results show significant alpha on equal weighted portfolios similar to the results 
obtained from the US markets (Eberhart, Maxwell, Siddique; 2004). Contrary to the US study, the 
value weighted portfolios do not present statistically significant returns, although the value weighted 
do portray economically significant abnormal returns excluding the long-short portfolios. 
In addition to the alphas, factor loadings provide additional insights on the companies. The equal 
weighted portfolio returns seem to be driven by small stocks which is to be expected. However, the 
positive loading on CMA factor reveals that the equal weighted portfolio firms are also alike to 
companies that invest conservatively. Value weighted portfolio factor loadings are very different to 
its equal weighted counterpart. Negative loadings in HML and RMW factors indicate that the large 
cap stocks have low book to market (high market to book) ratios and that they generally have weak 
profitability. Negative UMD factor is consistent with earlier findings (Eberhart, Maxwell, Siddique 
(2004) 
To summarize the findings of Fama French factor regressions. It seems that the positive R&D return 
predictability is not applicable to large cap stocks but instead is present in the smaller stocks. In 
addition, the large cap stocks with significant R&D increases seem to be growth stocks that exhibit 
weak profitability. Keeping in mind the heavy high technology industry weight of the portfolios it 
seems that markets have high confidence in these large cap stocks with significant R&D increases. I 
hypothesize that this high confidence leads to reduced R&D return predictability. It could be that 
investors have high confidence to the R&D activity of these large cap stocks whereas this same 






Below tables represent regression results for equal weighted and value weighted portfolios that measure returns 
of firms with significant R&D Increases. Intercept measures the abnormal returns (𝛼𝛼) generated by the 
portfolios. Coefficients b, s, h, r & c represent the factor coefficients. Time series length is 354 months. 
Statistical significance is marked by * -symbols. Five percent significance is marked by a one * -symbol. One 
percent significance is marked by ** -symbol and zero percent significance is marked by ***-symbol. 
Fama French three-factor regression results 
Equal Weighted   Value Weighted 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,570 0,194 2,945**   Intercept 0,318 0,282 1,126 
b 0,529 0,029 18,343***   b 0,519 0,042 12,353*** 
s 0,597 0,086 6,961***   s -0,564 0,125 -4,52*** 
h -0,068 0,057 -1,188   h -0,641 0,083 -7,699*** 
R squared = 0,529   R squared = 0,482 
                   
Long-Short Equal Weighted   Long-Short Value Weighted 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,318 0,125 2,539**   Intercept -0,219 0,276 -0,794 
b 0,054 0,019 2,884**   b 0,028 0,041 0,683 
s 0,153 0,056 2,753**   s -0,452 0,122 -3,71** 
h -0,044 0,037 -1,188   h -0,631 0,081 -7,755*** 
R squared = 0,0476   R squared = 0,2022 
                  
                  
                  
Fama French five-factor regression results 
Equal Weighted   Value Weighted 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,681 0,206 3,308**   Intercept 0,406 0,300 1,353 
B 0,508 0,033 15,587***   b 0,506 0,047 10,664*** 
S 0,577 0,087 6,664***   s -0,580 0,126 -4,594*** 
H -0,052 0,066 -0,785   h -0,657 0,096 -6,828*** 
R -0,210 0,135 -1,553   r -0,209 0,197 -1,061 
C -0,112 0,141 -0,789   c 0,020 0,206 0,097 
R squared = 0,5326   R squared = 0,484 
                  
Long-Short Equal Weighted   Long-Short Value Weighted 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,281 0,132 2,13*   Intercept -0,089 0,289 0,306 
b 0,072 0,021 3,436***   b 0,025 0,046 0,541 
s 0,159 0,055 2,875**   s -0,476 0,121 -3,918*** 
h -0,111 0,042 -2,636**  h -0,743 0,093 -8,018*** 
r -0,018 0,086 -0,203   r -0,432 0,190 -2,282* 
c 0,273 0,090 3,013**   c 0,364 0,198 1,834 





Below tables represent regression results for equal weighted and value weighted portfolios that measure returns 
of firms with significant R&D Increases. Intercept measures the abnormal returns (𝛼𝛼) generated by the 
portfolios. Coefficients b, s, h, & u represent the factor coefficients. Time series length is 354 months. 
Statistical significance is marked by * -symbols. Five percent significance is marked by a one * -symbol. One 
percent significance is marked by ** -symbol and zero percent significance is marked by ***-symbol.  
Carhart four-factor regression results 
Equal Weighted   Value Weighted 
Coefficient Value Std Dev T-Value   Coefficient Value Std Dev T-Value 
Intercept 0,694 0,192 3,619***   Intercept 0,509 0,278 1,828 
b 0,501 0,029 17,229***   b 0,475 0,042 11,258*** 
s 0,609 0,084 7,262***   s -0,545 0,122 -4,473*** 
h -0,062 0,056 -1,115   h -0,633 0,081 -7,787*** 
u -0,132 0,032 -4,103***   u -0,203 0,047 -4,362*** 
R squared = 0,5509   R squared = 0,5088 
                 
Long-Short Equal Weighted   Long-Short Value Weighted 
Coefficient Value Std Dev T-Value   Coefficient Value Std Dev T-Value 
Intercept 0,369 0,126 2,926**   Intercept 0,008 0,269 0,030 
b 0,042 0,019 2,215*   b -0,024 0,041 0,593 
s 0,158 0,055 2,865**   s -0,429 0,117 -3,656*** 
h -0,042 0,037 1,135   h -0,621 0,078 -7,925*** 
u -0,053 0,021 -2,54*   u -0,241 0,045 -5,361*** 
R squared = 0,06489   R squared = 0,2629 
 
5.2 Regression Results for Subsamples 
 
Chan et al (2001) show that positive return predictability only exists in tech companies with poor past 
performance meaning that the positive return predictability is only applicable to these companies. It 
is salient to look at the sample firm performance before significant R&D increases to see whether 
there is underperformance that could cause the positive return predictability, in addition I will regress 
a low tech subsample to see if the R&D return predictability is applicable to them, since there exists 
empirical evidence that abnormal returns are lower for non-high technology stocks (Eberhart, 
Maxwell, Siddique: 2004). The regression results are showcased in tables four and five. The firms do 
not experience abnormal returns before R&D increases, which contradicts the poor performance 
theory (Chan, Lakonishok, Sougiannis: 2001).  
However, I find that subsample portfolios excluding high technology stocks do not experience any 
significant abnormal returns albeit they are economically significant. I interpret these results so that 
investors react to R&D increases in non-high technology stocks correctly and these results show 





Below tables represent regression results for equal weighted and value weighted portfolios that test firm 
performance 36 months before the R&D increases. Intercept measures the abnormal returns (𝛼𝛼) generated by 
the portfolios. Coefficients b, s, h, r & c represent the factor coefficients. Time series length is 343 months. 
Statistical significance is marked by * -symbol. Five percent significance is marked by a one * -symbol. One 
percent significance is marked by ** -symbol. and zero percent significance is marked by ***-symbol. 
 
Fama French three-factor regression results 
Equal Weighted pre R&D increase   Value Weighted pre R&D increase 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0.597 0.232 1,931   Intercept 0,899 0,523 1,719 
b 0.619 0,027 16,601***   b 0,725 0,077 9,372*** 
s 0.550 0,080 6,623***   s -0,976 0,230 -4,245*** 
h 0.160 0,054 -0,361   h -0,738 0,153 -4,827*** 
R squared = 0,5344   R squared = 0,3475 
                  
Long-Short Equal Weighted pre R&D increase   Long-Short Value Weighted pre R&D increase 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,328 0,179 1,830   Intercept 0,334 0,502 0,666 
b 0,148 0,026 5,57***   b 0,264 0,074 3,558*** 
s 0,090 0,079 1,137   s -0,861 0,221 -3,900*** 
h -0,145 0,052 -2,761**   h -0,786 0,147 -5,352*** 
R squared = 0,1289   R squared = 0,1896 
   
 
Table 6 
Below tables represent regression results for equal weighted and value weighted portfolios that test ex high 
tech high R&D firm performance. Intercept measures the abnormal returns (𝛼𝛼) generated by the portfolios. 
Coefficients b, s, h, r & c represent the factor coefficients. Time series length is 354 months. Statistical 
significance is marked by * -symbol. Five percent significance is marked by a one * -symbol. One percent 
significance is marked by ** -symbol and zero percent significance is marked by ***-symbol. 
 
Fama French three-factor regression results 
Equal Weighted ex high tech   Value Weighted ex high tech 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,350 0,181 1,931   Intercept 0,203 0,193 1,051 
b 0,449 0,027 16,601***   b 0,297 0,029 10,311*** 
s 0,532 0,080 6,623***   s 0,015 0,086 0,171 
h -0,019 0,054 -0,361   h 0,173 0,057 3,02** 
R squared = 0,4762   R squared = 0,2345 
                  
Long-Short Equal Weighted ex high tech   Long-Short Value Weighted ex high tech 
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,062 0,138 0,451   Intercept 0,338 0,195 1,730 
b -0,034 0,020 -1,686   b 0,196 0,029 6,764*** 
s 0,080 0,061 1,315   s 0,124 0,086 1,448 
h -0,003 0,040 -0,074   h 0,181 0,057 3,172** 




6. Robustness Checks 
 
6.1 Risk Based Explanation for Return Predictability 
 
Since the results I have obtained in the section five using factor models show some level of return 
predictability, I find it salient to test whether this predictability is explained by the increased risk in 
R&D intensive firms. Gu (2015) shows that the positive R&D return predictability is caused by 
increased exposure to systematic firm. This increased systematic risk results from the fact that when 
firms enter innovation races, a large part of the firm value is tied into the future cash flows that rely 
on the R&D project.  
It should be noted that there exists evidence between distress risk, financial constraints and R&D 
return predictability (Li: 2011, Gu: 2015), but these studies treat R&D as a firm attribute, while in 
this study I am interested in measuring the effects of R&D increases (investments). Therefore, distress 
risk and constraints approaches are not directly applicable to this study. 
I will measure the exposure by comparing bear market subsamples. It should be reasonable to assume 
that if the systematic risk approach is correct, the sample firms should experience large exposures to 
market risk or underperformance since the firm value is largely tied to prospects in the future. I define 
a bear market as a two-year period following a -20% market return. I regress this sub sample to the 
market returns to estimate betas during bear market with the following model. Where Bear is a 
dummy variable that equals to 1 if markets have had a -20% return within 24 months.  
 
𝑆𝑆𝐵𝐵𝐵𝐵𝑟𝑟𝑝𝑝(𝑅𝑅𝑝𝑝𝑝𝑝 − 𝑅𝑅𝑓𝑓𝑝𝑝) = 𝛼𝛼 +  𝑆𝑆𝐵𝐵𝐵𝐵𝑟𝑟𝑝𝑝  𝑏𝑏𝑝𝑝�𝑅𝑅𝑀𝑀𝑀𝑀𝑀𝑀𝑝𝑝 − 𝑅𝑅𝑓𝑓𝑝𝑝� +  𝜀𝜀𝑝𝑝 
 
The results are showcased in table 6. It should be noted that the control portfolios include stocks that 
have had R&D expenses which means that the sample is skewed towards high-tech stocks similar to 
the sample portfolios. I find that the sample portfolios have around 2,7 percent larger market betas, 







Below tables represent regression results for equal weighted and value weighted portfolios that test 
sample firm exposure to market risk and performance during stock market turmoil (bear market). 
Intercept measures the abnormal returns (𝛼𝛼) generated by the portfolios. Coefficient b represents market 
beta. Time series length is 354 months and bear market month observation length were 48 months. 
Statistical significance is marked by * -symbol. Five percent significance is marked by a one * -symbol. 
One percent significance is marked by ** -symbol and zero percent significance is marked by ***-
symbol. 
 
Market Betas and Return Comparisons During Bear Market 
Equal Weighted       Value Weighted     
Coefficient Value Std Dev T-Value   Coefficient Value Std Dev T-Value 
Intercept 0,033 0,097 0,335   Intercept -0,110 0,104 -1,066 
b 0,383 0,030 12,714***   b 0,433 0,032 13,511*** 
R squared = 0,3147       R squared = 0,3415     
                  
Control Equal Weighted     Control Value Weighted   
Coefficient Value Std Dev T-Value   Coefficient Value Std Error T-Value 
Intercept -0,059 0,070 -0,841   Intercept 0,003 0,058 0,047 
b 0,373 0,022 17,293***   b 0,421 0,018 23,442*** 
R squared = 0,4593       R squared = 0,6084     
                  
Long Short Equal Weighted     Long Short Value Weighted   
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0.091 0.049 1.853   Intercept -0.113 0.09 -1.256 
b 0.01 0.015 0.661   b 0.012 0.028 0.435 
R squared = 0,0012       R squared = 0,00053     
 
In addition to the market betas, I estimated returns for long-short portfolios. I find that the equal 
weighted portfolio does not underperform the control group, but the value weighted portfolio seems 
to have slight underperformance. These results do not indicate that the R&D intensive firms are 
exposed to increased risk, and the value weighted underperformance is consistent with the growth 
firm characteristics. 
 
6.2 Accounting Standardization Subsamples  
 
As mentioned in the section 3.1, the sample has outlier values situated in the year 2005 that can be 
seen from the chart in appendix c. This outlier arises likely from the mandatory adoption of IAS/IFRS 
standards in the European Union. This adoption likely affects the sample companies reporting of 
R&D and other accounting figures and the new standards may not be comparable to the pre-2005 
R&D sample. To test if the samples are vastly different, I run regressions on two subsamples on years 




Below tables represent regression results for equal weighted and value weighted portfolios that test 
sample firm performance during two distinctive periods. Time series period is specified in the header 
above regression results. Intercept measures the abnormal returns (𝛼𝛼) generated by the portfolios. 
Coefficients b, s, h, r & c represent the factor coefficients. Time series lengths are 180 & 174 months 
for the 1990-2004 & 2006-2019 samples, respectively. Statistical significances are marked by * -
symbols. Five percent significance is marked by a one * -symbol. One percent significance is marked 
by ** -symbol and zero percent significance is marked by ***-symbol. 
 
Fama French three-factor regression results 
1990 – 2004 Equal Weighted     1990 – 2004 Value Weighted   
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,612 0,311 1,985*   Intercept 0,755 0,462 1,633 
b 0,603 0,046 13,092***   b 0,667 0,068 9,754*** 
s 0,456 0,123 3,733***   s -0,780 0,182 -4,393*** 
h -0,030 0,078 0,574   h -0,571 0,115 -4,969*** 
R squared = 0,5311   R squared = 0,581 
                  
2005-2019 Equal Weighted     2005-2019 Value Weighted   
Coefficient Value Std Error T-Value   Coefficient Value Std Error T-Value 
Intercept 0,576 0,229 2,518*   Intercept -0,02 0,304 -0,075 
b 0,447 0,036 12,374***   b 0,349 0,048 7,260*** 
s 0,772 0,117 6,585***   s -0,311 0,156 -1,993* 
h 0,047 0,104 0,447   h -0,422 0,139 -3,041** 
R squared = 0,4128   R squared = 0,2835 
 
Table 7 results show that the subsample portfolios do generate significant abnormal returns for equal 
weighted portfolios in both periods. However, the value weighed portfolio during the period 2005-
2019 generates slightly negative returns. I do not find this slightly negative return concerning since it 
does not contradict the results obtained in section 5. In addition, decreased observation periods are 
likely too short for long-term return measurement especially when I consider the five-year holding 
periods for the stocks. Therefore, I find it likely that the lower abnormal return of the value weighted 











Do investors misprice increased R&D expensed in the Nordics? In this study I tried to answer this 
question by following Eberhart et al (2004) methodology of measuring long term abnormal returns 
in companies that have had sudden and significant R&D increases. My main hypothesis in this study 
was that investors misprice R&D increases due to the intangible nature of the benefit that these 
investments provide which leads to positive R&D return predictability. 
My results provide evidence that firms with unexpected and significant R&D increases generate 
positive abnormal returns when the holding period for these firms is 60 months in the portfolio. 
However, the positive R&D return predictability is not observed in all companies. Value weighted 
portfolios that have increased exposure to large cap firms are not able to generate positive abnormal 
returns for companies with R&D increases. Additionally, the sample portfolios are heavily skewed 
towards technology and healthcare industries which can be considered high technology industries 
(Chan, Martin, Kensinger: 1990). When I exclude the high technology companies from the sample 
portfolios, I do not find any significant abnormal returns, albeit the returns can be considered 
economically significant. Portfolio performance preceding R&D increases is not significantly 
negative nor positive which indicates that the underreaction is not limited to poor performing 
technology companies (Chan, Lakonishok: 2001). 
Deducing from these results, I cannot accept my hypothesis H1 of investor underreaction to be 
applicable to all companies. It seems that markets are able to value large cap and non high technology 
companies correctly. However, I cannot reject my hypothesis either, since the significant and 
consistent abnormal returns in equal weighted portfolios show that investor underreaction seems to 
be present in smaller companies that operate in high technology industries. Therefore, my hypothesis 
H1 is applicable to small and mid cap companies only. 
It seems that Nordic markets treat R&D projects differently among different size firms. The lack of 
abnormal returns in large cap firms could mean that investors have higher confidence in their 
capability of creating successful innovations through R&D increases, this confidence is then priced 
in the stock prices which is shown by the low book to market ratios. This same reaction cannot be 
observed in the smaller companies, which means that investors underestimate the future benefits of 
R&D projects in these companies. This underreaction is reflected by higher book to market ratios and 
the significant abnormal returns. Compared to international results, it seems that Nordic investors do 
have a more optimistic stance towards R&D investments in large high technology companies. 
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In addition to the size factor, it seems that the R&D return predictability is industry specific. Positive 
R&D return predictability was shown only in the equal weighted portfolio that skews towards high 
technology industries. This implicates that investors find high technology R&D projects harder to 
value in high technology industries, which seems to be rather intuitive. 
My results and conclusions are consistent with the latest empirical literature (Chan, Martin, 
Kensinger: 1990, Chan, Lakonishok, Sougiannis: 2001, Eberhart, Maxwell, Siddique: 2004, Cohen, 
Diether, Malloy: 2013). However, I find my results to be inconsistent with the risk-based explanation 
of the R&D return predictability (Gu: 2015, Zhang: 2015). I find the decreased book to market 




Abdel Agami, Norvald Monsen, An appraisal of efforts by the Nordic countries toward accounting 
standards harmonization, Journal of International Accounting, Auditing and Taxation, Volume 4, 
Issue 2, 1995, Pages 185-203, ISSN 1061-9518, https://doi.org/10.1016/1061-9518(95)90017-9. 
(http://www.sciencedirect.com/science/article/pii/1061951895900179) 
Carhart, M.M. (1997), On Persistence in Mutual Fund Performance. The Journal of Finance, 52: 57-
82. doi:10.1111/j.1540-6261.1997.tb03808.x 
Chan, L.K.C., Lakonishok, J. and Sougiannis, T. (2001), The Stock Market Valuation of Research 
and Development Expenditures. The Journal of Finance, 56: 2431-2456. doi:10.1111/0022-
1082.00411 
DANIEL, K. and TITMAN, S. (2006), Market Reactions to Tangible and Intangible Information. 
The Journal of Finance, 61: 1605-1643. doi:10.1111/j.1540-6261.2006.00884.x 
Dongmei Li, Financial Constraints, R&D Investment, and Stock Returns, The Review of Financial 
Studies, Volume 24, Issue 9, September 2011, Pages 2974–3007, https://doi.org/10.1093/rfs/hhr043 
Eberhart, A.C., Maxwell, W.F. and Siddique, A.R. (2004), An Examination of Long‐Term 
Abnormal Stock Returns and Operating Performance Following R&D Increases. The Journal of 
Finance, 59: 623-650. doi:10.1111/j.1540-6261.2004.00644.x 
Eugene F. Fama, Market efficiency, long-term returns, and behavioral finance, Journal of Financial 





Eugene F. Fama, Kenneth R. French, A five-factor asset pricing model, Journal of Financial 
Economics, Volume 116, Issue 1, 2015, Pages 1-22, ISSN 0304-405X, 
https://doi.org/10.1016/j.jfineco.2014.10.010. 
(http://www.sciencedirect.com/science/article/pii/S0304405X14002323) 
FAMA, E.F. and FRENCH, K.R. (1992), The Cross‐Section of Expected Stock Returns. The 
Journal of Finance, 47: 427-465. doi:10.1111/j.1540-6261.1992.tb04398.x 
Jonathan B. Berk, Richard C. Green, Vasant Naik, Valuation and Return Dynamics of New 
Ventures, The Review of Financial Studies, Volume 17, Issue 1, January 2004, Pages 1–35, 
https://doi.org/10.1093/rfs/hhg021 
Lauren Cohen, Karl Diether, Christopher Malloy, Misvaluing Innovation, The Review of Financial 
Studies, Volume 26, Issue 3, March 2013, Pages 635–666, https://doi.org/10.1093/rfs/hhs183 
Lifeng Gu, Product market competition, R&D investment, and stock returns, Journal of Financial 
Economics, Volume 119, Issue 2, 2016, Pages 441-455, ISSN 0304-405X, 
https://doi.org/10.1016/j.jfineco.2015.09.008. 
(http://www.sciencedirect.com/science/article/pii/S0304405X15001750) 
Su Han Chan, John D Martin, John W Kensinger, Corporate research and development expenditures 
and share value, Journal of Financial Economics, Volume 26, Issue 2, 1990, Pages 255-276, ISSN 
0304-405X, https://doi.org/10.1016/0304-405X(90)90005-K. 
(http://www.sciencedirect.com/science/article/pii/0304405X9090005K) 
Wei Zhang, R&D investment and distress risk, Journal of Empirical Finance, Volume 32, 2015, 












Below table shows the industry distribution of the sample companies. The company industry is based on Thomson 
Business Classification. It should be noted that financials classification includes companies that participate in producing 
financial applications or technology. Thomson Business Classification was not available to all sample companies. High 
technology are classified using Chan et al (1990) methodology and these industries have “Y” mark next to them in High 
Technology column.  
Distribution of sample stocks between industries  
Industry  Share of Sample Firms 
High 
Technology 
Energy 1,13 % N 
Basic Materials 4,52 % N 
Industrials 19,21 % N 
Cyclical Consumer Goods & Services 7,34 % N 
Non-Cyclical Consumer Goods & Services 2,82 % N 
Financials 2,82 % N 
Healthcare 35,03 % Y 
Technology 25,99 % Y 
Utilities 1,13 % N 
   
 
Appendix B 
Below table shows the industry distribution of the sample companies. The company industry is based on Thomson 
country Classification.  
Distribution of sample stocks between 
countries   
Country   
Finland 18,55 % 
Sweden 45,70 % 
Denmark 13,12 % 
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